1. Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy
- Author
-
Sebastian F. Schoppmann, Yi-Chien Tsai, Richard Grose, Dariga Ramazanova, Christina Fassnacht, Dagmar Kollmann, Emmanuella Guenova, Sanja Radosavljevic, Matthias Preusser, Robin Ristl, Lavinia Wilfing, Aysegül Ilhan-Mutlu, and Gerd Jomrich
- Subjects
Programmed cell death ,PD-L2 ,medicine.medical_treatment ,Adenocarcinoma of the gastroesophageal junction ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Preoperative chemotherapy ,Tumor microenvironment ,Chemotherapy ,biology ,business.industry ,Surgery ,Immunotherapy ,Neoadjuvant therapy ,3. Good health ,030220 oncology & carcinogenesis ,Cancer cell ,biology.protein ,Cancer research ,Immunohistochemistry ,Original Article ,030211 gastroenterology & hepatology ,Antibody ,business ,Abdominal surgery - Abstract
Summary Background The effects of cytotoxic chemotherapy on the expression of programmed death ligand 2 (PD-L2) are unknown and little is known about how the tumor microenvironment changes following neoadjuvant chemotherapy in locally advanced gastroesophageal adenocarcinomas (AEG). Recently, a number of studies reported that cytotoxic chemotherapy affects the expression levels of programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1). Regarding PD-L2, the second known ligand of PD‑1, no data on potential changes in expression patterns in patients with preoperatively treated AEG are available. The aim of this study was to investigate the impact of cytotoxic chemotherapy on PD-L2 expression in patients with resectable AEG. Methods Consecutive patients with locally advanced AEG treated with preoperative cytotoxic chemotherapy were included. PD-L2 expression by cancer cells (CCs) and tumor-infiltrating lymphocytes (TILs) was investigated in samples of paired diagnostic biopsies and resected tumor specimens by immunohistochemistry using two different anti-PD-L2 antibodies. Results Included were 40 patients with AEG and available paired tumor tissue samples. PD-L2 expression was observed in one diagnostic biopsy sample by CCs and in one diagnostic biopsy sample by TILs. There was no difference concerning the expression levels measured by the two antibodies. Conclusion In contrast to previously published studies reporting PD-L2 expression rates of up to 50% in AEGs, in our cohort, PD-L2 expression seems to play no significant role in AEG.
- Published
- 2021